229 related articles for article (PubMed ID: 17477035)
21. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
Ray G; Pal S; Nayyar I; Dey S
Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
[TBL] [Abstract][Full Text] [Related]
22. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
23. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
25. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
[TBL] [Abstract][Full Text] [Related]
26. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
27. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
28. Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.
Elefsiniotis IS; Pantazis KD; Fotos NV; Moulakakis A; Mavrogiannis C
J Gastroenterol Hepatol; 2006 Mar; 21(3):622-3. PubMed ID: 16638114
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Dumortier J; Scoazec JY; Chevallier P; Boillot O
J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
[TBL] [Abstract][Full Text] [Related]
30. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
Krawitt EL; Gordon SR; Grace ND; Ashikaga T; Ray MA; Palmer M; Yarze JC; Moskowitz S;
Am J Gastroenterol; 2006 Jun; 101(6):1268-73. PubMed ID: 16771948
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports.
Hegade VS; Sood R; Saralaya D; Moreea S
Ann Hepatol; 2013; 12(4):629-33. PubMed ID: 23813142
[TBL] [Abstract][Full Text] [Related]
32. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
33. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
Gentile I; Viola C; Reynaud L; Borrelli F; Cerini R; Ciampi R; Piazza M; Borgia G
J Interferon Cytokine Res; 2005 May; 25(5):283-5. PubMed ID: 15871666
[TBL] [Abstract][Full Text] [Related]
34. [Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
Stránský J; Rýzlová M; Stríteský J; Nĕmecek V
Cas Lek Cesk; 2002 Jun; 141(11):351-4. PubMed ID: 12099059
[TBL] [Abstract][Full Text] [Related]
35. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
[No Abstract] [Full Text] [Related]
36. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
Kowala-Piaskowska A; Mozer-Lisewska I; Figlerowicz M; Słuzewski W
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
[TBL] [Abstract][Full Text] [Related]
39. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
Arora A; Vargas L; Kuzniar TJ
J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589
[TBL] [Abstract][Full Text] [Related]
40. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
